(Q43257605)

17 November 2017

title

Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel (English)

1 reference

17 November 2017

1 reference

Y Nishiya

1

1 reference

17 November 2017

K Hagihara

2

1 reference

17 November 2017

A Kurihara

3

1 reference

17 November 2017

N Okudaira

4

1 reference

17 November 2017

N A Farid

5

1 reference

17 November 2017

O Okazaki

6

1 reference

17 November 2017

T Ikeda

7

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

39

1 reference

17 November 2017

issue

11

1 reference

17 November 2017

page(s)

836-843

1 reference

Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

The potential use of mechanism-based enzyme inactivators in medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498250903191427

10.3109/00498250903191427

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference